[Steroid hormones in plasma and aqueous of bovine eye].

Ľ. Stárka,R. Hampl,M. Bičı́ková,J. Obenberger

1977-03-01

Abstract:

What problem does this paper attempt to address?

Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation

Tao Wang,Zheng Lv,Huayi Feng,Jinlong Li,Bo Cui,Yang Yang,Xing Huang,Xiangyi Zhang,Xintao Li,Xin Ma

DOI: https://doi.org/10.3389/fonc.2022.860133

IF: 4.7

2022-01-01

Frontiers in Oncology

Abstract:PurposeTo investigate the significance of demographic and pathological characteristics on the survival outcomes of urachal adenocarcinoma (UrAC), primary bladder adenocarcinoma (BAC) and urothelial carcinoma with glandular differentiation (UCGD) in China. Materials and MethodsWe retrospectively analyzed cases with non-distant metastases (<= T4M0). Of 106 patients, 30 (28.3%), 40 (37.7%), and 36 (34.0%) met the criteria for UrAC, primary BAC, and UCGD, respectively. Data on patient demographics, tumor pathology, and survival outcomes were collected. The median follow-up was 36 months. Survival was analyzed using multivariate Cox regression. ResultsPatients with UrAC were younger (51.87 +/- 15.25 years) than those with primary BAC (60.50 +/- 12.56 years) and UCGD (63.83 +/- 11.60 years) (P<0.001). Patients with UrAC were the most likely to be stage T3-4 (70.0% vs. 40.0% vs. 44.4%; P<0.001), while the primary BAC group had a higher rate of poor differentiation than the UrAC and UCGD groups (57.4% vs. 18.5% vs. 24.1%; P<0.001). The Kaplan-Meier curves showed that the overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) of the primary BAC group were poorer than those of both the UrAC and UCGD groups (P=0.0046,P<0.0001,P=0.0077 respectively). Regarding BAC, patients with mucinous adenocarcinoma tended to have better OS and PFS than those with other histological types (P<0.005,P=0.0245). Multivariate Cox regression analysis revealed that tumor type (P=0.002), T stage (P=0.034), and the age-adjusted Charlson Comorbidity Index (aCCI) scores (P=0.005) predicted the postoperative OS and DSS of the patients. For PFS, the tumor type (P=0.011), grade (P=0.000), and aCCI (P=0.002) scores were predictive. ConclusionAmong UrAC, primary BAC, and UCGD patients, the prognosis was poorest for those with primary BAC. Attempts should be made to diagnose these aggressive tumors early, since patients in whom tumors are detected early appear to survive longer.
Upper urinary tract tumors developing after bladder transitional cell cancer

YU Jiandi,ZHANG Zhigen,ZHENG Danye,WANG Ping

DOI: https://doi.org/10.3969/j.issn.1001-1420.2006.06.011

2006-01-01

Journal of Clinical Urology

Abstract:Objective To study the incidence and characteristics of metachronous upper urinary tract transition al cell cancer(UUT TCC)in patients with primary bladder tumor,and evaluate the eharaeteristics of bladder tumors related to UUT TCC.Methods:We retrospectively studied the incidence and clinic characteristic of UUT TCC among 637 eases of bladder tumor(122 with superficial bladder cancer and 215 with invasive bladder cancer). Results:16 cases were developed whh metachronous UUT TCC(10 patients were in superficial group and 6 pa- tients in invasive group).The ineidence of UUT TCC was not statistically significant(P＞0.05)between superfi eial group and invasive group,the same result was attained between intermediate risk group and high risk group in superficial bladder cancer.The incidence of UUT TCC were significantly higher in patients at intermediate risk and high risk group than in those at low risk(P＜0.05).Conclusions:High tumor pathologie stages.tumor multi plicity,concomitant carcinoma in situ were risk factors related to metachronous UUT TCC after diagnosis and treatment of primary bladder cancer.UUT TCC after treatment of invasive bladder cancer tends to have a relatively poor prognosis.
AB063. Comparisons of prognosis between urothelial carcinoma of the upper urinary tract and bladder with pT3-4 diseases

Xiaohong Su,Qi Tang,Dong Fang,Gengyan Xiong,Qun He,Lei Zhang,Pei Liu,Yu Fan,Han Hao,Xuesong Li,Liqun Zhou,Nirmish Singla

DOI: https://doi.org/10.21037/tau.2016.s063

2016-01-01

Translational Andrology and Urology

Abstract:Objective: To compare the prognosis of locally advanced upper tract urothelial carcinoma (UTUC) and bladder cancer (BC) in patients treated with radical surgeries. Methods: A retrospective analysis of the clinicopathological data of 228 consecutive UTUC patients and 174 BC patients treated by radical surgeries from 2000 to 2012 at a high-volume center in China was conducted. Kaplan-Meier method and Cox regression were used to compare overall survival (OS) and cancer-specific survival (CSS) and to find prognostic factors. Results: BC were associated with male sex (P<0.001), high grade (P=0.002), multifocality (P<0.001), positive lymph node (P=0.002), no hydronephrosis (P<0.001) and open surgical approach (P<0.001). UTUC have statistically significant better 5-year CSS rate (61.0% vs. 49.8%, P=0.008) and OS rate (58.3% vs. 37.4%, P<0.001) than BC. Bladder tumor location [UTCU vs. BC: hazard ratio (HR) =0.703 and HR =0.462] and positive lymph node status (HR =1.919 and HR =1.667) were independent risk factors of cancer-specific death and overall mortality, respectively. Conclusions: Our data suggest that locally invasive urothelial carcinomas (UC) behave differently in the upper and lower urinary tracts. UTUC has a better prognosis than BC when stage and grade are considered simultaneously and lymph node involvement has significant influences on clinical outcomes of urothelial carcinoma.
Incidence, characteristics, treatment strategies, and oncologic outcomes of synchronous bilateral upper tract urothelial carcinoma in the Chinese population.

Dong Fang,Gengyan Xiong,Xuesong Li,Yongming Kang,Lei Zhang,Guangzhi Zhao,Xiaopeng Chen,Lin Yao,Xiaoyu Zhang,Wei Yu,Kan Gong,Yi Song,Qun He,Zhisong He,Liqun Zhou,Yinglu Guo

DOI: https://doi.org/10.1016/j.urolonc.2014.07.001

2014-01-01

Abstract:OBJECTIVES:To investigate the incidence and treatment strategies for bilateral upper tract urothelial carcinoma (UTUC) and to compare the characteristic and oncologic outcomes of bilateral UTUC with those of unilateral tumors. METHODS AND MATERIALS:The study included 892 consecutive patients with UTUC. Bilateral UTUC was defined as synchronous bilateral carcinoma on preoperative imaging before confirmation by pathology or positive urine cytology result plus direct visualization. Radical nephroureterectomy (RNU) or nephron-sparing surgery (NSS) or both were carried out. RESULTS:A total of 39 patients (4.37%) suffered from bilateral disease. Discordant histological grade of bilateral tumor was found in 39.3% cases. Bilateral tumors were associated with female sex (P<0.001), preoperative renal insufficiency (P<0.001), previous or concomitant bladder tumors (P = 0.013), lower tumor stages (P = 0.020), papillary architecture (P = 0.001), and smaller-sized tumors (P = 0.020). Patients with worse renal function (P<0.001) or large-sized tumors (P = 0.039) tended to be treated with bilateral RNU. Most patients (67.6%) were treated with unilateral RNU plus unilateral NSS, with NSS being performed on tumors that only extended to the ureter (P = 0.003) and had a smaller size (P = 0.005). The median follow-up duration was 56 months. The 5-year cancer-specific survival and bladder recurrence-free survival rates were 81.2% and 64.5%, respectively, similar to those of unilateral tumors. Male sex (hazard ratio = 11.535) and higher tumor stage (hazard ratio = 3.386) were independent worse prognostic factors. CONCLUSIONS:The prevalence of bilateral UTUC is rare. Female patients, patients with renal insufficiency, and those with bladder tumor tended to suffer from bilateral disease and were less likely to present with worse pathological outcomes in the Chinese population. The tumor characteristics and renal function were informative in treatment selection. The oncologic outcomes were similar to those in unilateral UTUC, and male sex and a higher tumor stage were poor prognostic factors for these patients.
Comparisons Of Prognosis Between Urothelial Carcinoma Of The Upper Urinary Tract And Bladder With Pt3-4 Cancer

Xiaohong Su,Qi Tang,Dong Fang,Gengyan Xiong,Nirmish Singla,Qun He,Lei Zhang,Pei Liu,Yu Fan,Han Hao,Xuesong Li,Liqun Zhou

2016-01-01

Abstract:The oncological outcomes of upper tract urothelial carcinoma (UTUC) and bladder cancer (BC) in patients treated with radical surgeries remains controversial. A retrospective analysis of the clinicopathologicla data of 228 consecutive UTUC patients and 174 BC patients treated with radical surgeries from 2000 to 2012 at a high-volume center in China was conducted. Kaplan-Meier method and Cox regression were used to compare overall survival (OS) and cancer-specific survival (CSS) and to find prognostic factors. In this cohort of patients, BC were associated with male sex (P<0.001), multifocality (P<0.001), positive lymph node (P=0.002), no hydronephrosis (P<0.001) and open surgical approach (P<0.001). UTUC have statistically significant better 5-year CSS rate (61.0% vs. 49.8%, P=0.008) and OS rate (58.3% vs. 37.4%, P<0.001) than BC. Bladder tumor location (UTCU vs. BC: hazard ratio (HR)=0.703 and HR=0.462) and positive lymph node status (HR=1.919 and HR=1.667) were independent risk factors of cancer-specific death and overall mortality, respectively. Our data suggest that locally invasive urothelial carcinomas (UC) behave differently in the upper and lower urinary tracts. UTUC has a better prognosis than BC when stage and grade are considered simultaneously and lymph node involvement has significant influences on clinical outcomes of urothelial carcinoma.
MEMBRANE MARKERS OF LYMPHOCYTES IN LYMPHOMAS, MELANOMA AND LUPUS ERYTHEMATOSUS

R. Edelson

DOI: https://doi.org/10.1111/j.1365-4362.1976.tb04892.x

1976-10-01

International Journal of Dermatology

Abstract:Of the clinical specialties, dermatology is likely to be among the most profoundly affected by the developing discipline of cellular immunology. The diversity of cutaneous infiltrative processes, the accessibility of the skin for study and the number of differentiated cell types and cell products in that organ offer the cellular immunologist special opportunities and challenges. As I will emphasize in this brief review, insights into the cellular immunology of selected dermatologic processes have already contributed to our understanding of those disorders. The single most important point that will be made here is that as advances of substantial relevance to both clinical dermatologists and cellular immunologists accumulate, it becomes increasingly necessary that the lines of communication between these 2 groups remain open. In this paper, I have emphasized recent observations from the investigation of the cutaneous lymphomas, melanomas, nevi and lupus erythematosus.
Incidence, Characteristics, Treatment Strategies, and Oncologic Outcomes of Synchronous Bilateral Upper Tract Urothelial Carcinoma in the Chinese Population1these Authors Contribute Equally.

Dong Fang,Gengyan Xiong,Xuesong Li,Yongming Kang,Lei Zhang,Guangzhi Zhao,Xiaopeng Chen,Lin Yao,Xiaoyu Zhang,Wei Yu,Kan Gong,Yi Song,Qun He,Zhisong He,Liqun Zhou,Yinglu Guo

DOI: https://doi.org/10.1016/j.urolonc.2014.07.001

IF: 2.954

2015-01-01

Urologic Oncology Seminars and Original Investigations

Abstract:To investigate the incidence and treatment strategies for bilateral upper tract urothelial carcinoma (UTUC) and to compare the characteristic and oncologic outcomes of bilateral UTUC with those of unilateral tumors.The study included 892 consecutive patients with UTUC. Bilateral UTUC was defined as synchronous bilateral carcinoma on preoperative imaging before confirmation by pathology or positive urine cytology result plus direct visualization. Radical nephroureterectomy (RNU) or nephron-sparing surgery (NSS) or both were carried out.A total of 39 patients (4.37%) suffered from bilateral disease. Discordant histological grade of bilateral tumor was found in 39.3% cases. Bilateral tumors were associated with female sex (P<0.001), preoperative renal insufficiency (P<0.001), previous or concomitant bladder tumors (P = 0.013), lower tumor stages (P = 0.020), papillary architecture (P = 0.001), and smaller-sized tumors (P = 0.020). Patients with worse renal function (P<0.001) or large-sized tumors (P = 0.039) tended to be treated with bilateral RNU. Most patients (67.6%) were treated with unilateral RNU plus unilateral NSS, with NSS being performed on tumors that only extended to the ureter (P = 0.003) and had a smaller size (P = 0.005). The median follow-up duration was 56 months. The 5-year cancer-specific survival and bladder recurrence-free survival rates were 81.2% and 64.5%, respectively, similar to those of unilateral tumors. Male sex (hazard ratio = 11.535) and higher tumor stage (hazard ratio = 3.386) were independent worse prognostic factors.The prevalence of bilateral UTUC is rare. Female patients, patients with renal insufficiency, and those with bladder tumor tended to suffer from bilateral disease and were less likely to present with worse pathological outcomes in the Chinese population. The tumor characteristics and renal function were informative in treatment selection. The oncologic outcomes were similar to those in unilateral UTUC, and male sex and a higher tumor stage were poor prognostic factors for these patients.
Predictive Value of Clinicopathological Markers for the Metachronous Bladder Cancer and Prognosis of Upper Tract Urothelial Carcinoma

Chenchen Feng,Lujia Wang,Guanxiong Ding,Qiang Ding,Zhongwen Zhou,Haowen Jiang,Zhong Wu

DOI: https://doi.org/10.1038/srep04015

IF: 4.6

2014-01-01

Scientific Reports

Abstract:Upper tract urothelial carcinoma (UTUC) is rare but aggressive with poor prognosis. We aimed to find effective predictive markers for recurrence and prognosis in UTUC patients. In this retrospective study, we included 88 UTUC patients treated with radical neprhoureterectomy (RNU) and analyzed their clinicopathological parameters. For study of incidence of metachronous bladder tumor, models were adjusted with inclusion of prophylactic intravesical instillation chemotherapy. The mean follow-up was 28.59 months (2 to 82 mo). Lack of gross hematuria (RR 0.060, 95%CI 0.008–0.468), tumor located at ureter (RR 0.037, 95%CI 0.004–0.378), advanced stage and higher p53 expression were independent factors for worse survival. Recurrence of bladder cancer occurred 20% of patients at median follow-up of 37.65 months (5 to 82 mo). Higher tumor grade (RR 5.998, 95%CI 1.359–26.479) and presence of ipsilateral non-functioning kidney at diagnosis (RR 5.982, 95%CI 1.338–26.750) were predictors for recurrence. The present study identified several parameters with predictive value in the prognosis and intravesicle recurrence in UTUCand shed light on the better monitoring and management of the disease.
Intravesical Recurrence after Radical Nephroureterectomy of Upper Urinary Tract Urothelial Carcinoma: A Large Population-Based Investigation of Clinicopathologic Characteristics and Survival Outcomes.

Jie Wu,Pei-Hang Xu,Wen-Jie Luo,Bo Dai,Yi-Jun Shen,Ding-Wei Ye,Yu-Chen Wang,Yi-Ping Zhu

DOI: https://doi.org/10.3389/fsurg.2021.590448

IF: 1.8

2021-01-01

Frontiers in Surgery

Abstract:Background: Of patients with upper urinary tract urothelial carcinoma (UTUC), 22–47% developed bladder recurrence after radical nephroureterectomy. Furthermore, the effect of surgery for UTUC-bladder cancer (BC) has not been well validated. The aim of this study was to assess the impact of standard primary BC surgical strategy on survival of patients diagnosed with UTUC-BC.Patients and Methods: A total of 676 UTUC-BC patients and 197,753 primary BC patients diagnosed from 2004 to 2016, were identified based on the SEER database. The Kaplan-Meier method and the Fine and Gray competing risks analysis were performed to assess overall survival (OS) and cancer-specific mortality (CSM). Multivariate Cox regression model and competing risks regression model were used to identify independent risk factors. Propensity score matching (PSM) was also performed to adjust potential confounding factors.Results: The baseline characteristics and survival outcomes of the two BC patient cohorts are quite different. For UTUC-BC patients, no significant difference in OS (NMIBC: p = 0.88; MIBC: p = 0.98) or cumulative incidence of CSM (NMIBC: p = 0.12; MIBC: p = 0.96) were noted for various surgical procedures. Local tumor treatment and partial cystectomy for UTUC-NMIBC patients produced lower 1-year (6.1%) and 3-year CSM (16.2%). Radical cystectomy for UTUC-MIBC patients produced lower 1-year (11.8%) but higher 3-year CSM (62.7%). After PSM for covariates, UTUC-BC patients still had a worse prognosis after surgery compared with primary BC patients. Based on regression models, older age, advanced T stage, N positive disease, M positive disease, and shorter interval between UTUC and BC were identified as independent risk factors for UTUC-BC patients.Conclusion: Standard primary BC surgical strategy did not provide significant survival benefit for UTUC-BC patients. Compared with primary BC patients, UTUC-BC patients had a worse prognosis after surgery, suggesting that current primary BC surgical guidelines are not entirely appropriate for UTUC-BC patients. Our findings underscore the continued importance and need for better prognosis and improved guidelines for management of UTUC-BC patients.
Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients

Dong Fang,Pei Liu,Xuesong Li,Gengyan Xiong,Lei Zhang,Nirmish Singla,Guangzhi Zhao,Qun He,Zhisong He,Liqun Zhou

DOI: https://doi.org/10.1038/srep18014

IF: 4.6

2015-01-01

Scientific Reports

Abstract:The incidence of pan-urothelial cell carcinoma (panUCC), which refers to the presence of both bilateral (UTUC) and bladder tumor (BT), is relatively low. However, the profile of a panUCC cohort of patients remains to be elucidated. We reviewed the data of consecutive UTUC patients who received treatment at our center from 1999 to 2012. Overall, 45 patients were included in this study, with a median age of 64.5 years. Fourteen patients initially presented with unilateral UTUC, 11 initially with BT and the remainder with multiple tumors. Patients with UTUC were more likely to manifest higher rates of muscle invasion and larger-sized tumors. Five patients were treated with complete urinary tract exenteration (CUTE) and most patients (73.3%) received combined management with conservative and radical surgery. After a median follow-up of 77 months, 18 patients (40%) died including 15 (33.3%) due to cancer. Higher tumor stage was the only risk factor predictive of worse survival. Nineteen patients experienced local recurrence after conservative surgery. This study indicated that PanUCC involves either synchronous or metachronous presentation of tumors with a high risk of tumor recurrence, progression and dissemination after conservative surgery.
Genetic Alterations in Chromatin Regulatory Genes in Upper Tract Urothelial Carcinoma and Urothelial Bladder Cancer

Shuo Wang,Xuzhi Yan,Weihua Lan,Yapeng Wang,Ze Wang,Dali Tong,Yao Zhang,Qiang Ran,Haoyang Li,Junhao Jin,Haiyang Xiao,Jing Xu,Qian Yan,Dianzheng Zhang,Qiang Ma,Hualiang Xiao,Jun Qin,Luofu Wang,Jun Jiang,Qiuli Liu

DOI: https://doi.org/10.1002/cam4.70398

IF: 4.711

2024-11-10

Cancer Medicine

Abstract:Purpose Upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB) share histomorphological and therapeutic features but distinct epidemiologic and clinicopathologic characteristics. We examined alterations of chromatin regulatory genes in molecular subtypes, clonal relatedness, and T‐cell receptor (TCR) diversity in UTUC and UCB. Materials and Methods Targeted next‐generation sequencing or whole‐exome DNA sequencing and TCR sequencing were conducted with 34 UTUC and 49 UCB specimens from 63 patients. Tumors were subtyped based on the expression of CK5 and GATA3. Results of tissue microarray of 78 muscle‐invasive bladder cancer (MIBC) samples were used as prognostic factors of different subtypes of MIBC. Results Chromatin regulatory genes were frequently mutated in both UTUC and UCB. Rapid relapse and progression of non‐MIBC are correlated with alterations of KMT2C and EP300. Frequency of alterations in chromatin regulatory genes is higher in UTUC patients with SBS22 and SBS2 signatures and lower in UCB patients with SBS2 and SBS6 signatures. GATA3 and CK5 double‐positive patients with higher frequencies of SMARCA4, ARID1A, and EP300 mutations have better prognoses than patients with basal subtypes. Although UTUC and UCB in the same patient can be either clonally related or developed independently, mutated genes in chromatin pathway were enriched in the related clones. Compared to UTUC, UCB had more deleterious mutations in DNA damage repair (DDR) genes, higher levels of tumor mutation burden (TMB) and copy number variations (CNVs), as well as higher TCR clonality and lower TCR diversity. Conclusions Since genetic alterations of the chromatin pathway genes are important in both UTUC and UCB, they could serve as potential biomarkers for predicting disease progression and therapeutic targets. Differences in mutation frequencies of DDR pathway, TMB, CNV, and TCR might be the contributing factors for the distinct responses to immune checkpoint inhibitor (ICI) between UTUC and UCB.

oncology
Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy

Qi Tang,Wei Zuo,Chong Wan,Shengwei Xiong,Chunru Xu,Changwei Yuan,Qiangqiang Sun,Liqun Zhou,Xuesong Li

DOI: https://doi.org/10.3389/fimmu.2022.1097730

2023-02-03

Abstract:Backgrounds: Despite the genomic landscape of urothelial carcinomas (UC) patients, especially those with UC of bladder (UCB), has been comprehensively delineated and associated with pathogenetic mechanisms and treatment preferences, the genomic characterization of upper tract UC (UTUC) has yet to be fully elucidated. Materials and methods: A total of 131 Chinese UTUC (74 renal pelvis & 57 ureter) and 118 UCB patients were enrolled in the present study, and targeted next-generation sequencing (NGS) of 618 cancer-associated genes were conducted to exhibit the profile of somatic and germline alterations. The COSMIC database, including 30 mutational signatures, were utilized to evaluate the mutational spectrums. Moreover, TCGA-UCB, MSKCC-UCB, and MSKCC-UTUC datasets were retrieved for preforming genomic alterations (GAs) comparison analysis between Western and Chinese UC patients. Results: In our cohort, 93.98% and 56.63% of UC patients were identified with oncogenic and actionable somatic alterations, respectively. Meanwhile, 11.24% of Chinese UC patients (of 14.50% and 7.63% of UTUC and UCB cases, respectively) were identified to harbor a total of 32 pathogenic/likely-pathogenic germline variants in 22 genes, with DNA damage repair (DDR)-associated BRCA1 (1.20%) and CHEK2 (1.20%) being the most prevalent. Chinese UTUC and UCB patients possessed distinct somatic genomic characteristics, especially with significantly different prevalence in KMT2D/C/A, GNAQ, ERCC2, RB1, and PPM1D. In addition, we also found notable differences in the prevalence of ELF3, TP53, PMS2, and FAT4 between renal pelvis and ureter carcinomas. Moreover, 22.90% and 33.90% of UTUC and UCB patients, respectively, had at least one deleterious/likely deleterious alteration in DDR related genes/pathways. Subsequently, mutational signature analysis revealed that UC patients with mutational signature 22, irrespective of UTUC or UCB, consistently had the markedly higher level of tumor mutational burden (TMB), which was proved to be positively correlated with the objective complete/partial response rate in the IMvigor210 cohort. By comparison, Chinese and Western UTUC patients also differed regrading GAs in oncogenic-related genes/pathways, especially in TP53, RTK/RAS, and PI3K pathways; besides, more alterations in WNT pathway but less TP53, RTK/RAS, HIPPO, and PI3K pathways were identified in Chinese UCB. Discussions: The in-depth analysis of genomic mutational landscapes revealed distinct pathogenetic mechanisms between Chinese UTUC and UCB, and specific genomic characterizations could identify high risk population of UTUC/UCB and provided information regarding the selection of alternative therapeutic regimens.
Risk factors and survival outcomes of metachronous contralateral upper tract urothelial carcinoma

Kan Wu,Jiayu Liang,Yiping Lu

DOI: https://doi.org/10.1038/s41598-020-73699-5

IF: 4.6

2020-10-06

Scientific Reports

Abstract:Abstract Because population-based risk estimates for metachronous contralateral UTUC are lacking. In this study, we aimed to evaluate the risk and survival of metachronous contralateral upper tract urothelial carcinoma (UTUC) on a large population-based level. A total of 23,075 patients were identified from the Surveillance, Epidemiology, and End Results database (1973–2015), 144 (0.6%) patients developed metachronous contralateral UTUC (median of 32 months after diagnosis). The cumulative incidence at 10, 20, and 30 years of follow-up was 1.1%, 1.6%, and 2.6%, respectively. We applied Fine and Gray’s competing risk regression model to determine the risk factors of a new contralateral, metachronous UTUC. The competing risk regression model demonstrated that older age (hazard ratio [HR] 0.75; 95% CI 0.67–0.85) and larger tumor size (HR 0.61; 95% CI 0.39–0.97) were associated with a significantly decreased risk of metachronous contralateral UTUC. However, bladder cancer presence was an independent risk factor for the development of contralateral tumors (HR 2.42; 95% CI 1.73–3.37). In addition, we demonstrated developing contralateral UTUC was not associated with poor prognosis by using Kaplan–Meier and multivariable analysis. Our findings suggest that metachronous contralateral UTUC is comparatively rare, and has not impact on survival. Importantly, patients with younger age, small tumours, and the presence of bladder cancer were more likely to develop a contralateral tumor, which may provide a rationale for lifelong surveillance in high-risk patients.

multidisciplinary sciences
Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder

Kaiwei Yang,Wei Yu,Huanhuan Liu,Feng Ding,Yanrui Zhang,Yun Zhang,Wang,Feng Lou,Shanbo Cao,Huina Wang,Zhisong He

DOI: https://doi.org/10.1002/onco.13839

2021-01-01

The Oncologist

Abstract:BACKGROUND:Different genomic characterization in urothelial carcinoma (UC) by site of origin may imply contrasting therapeutic opportunities and pathogenetic mechanisms. The aim of this study was to investigate whether differences between upper tract UC (UTUC) and UC of the bladder (UCB) result from intrinsic biological diversity.MATERIALS AND METHODS:We prospectively sequenced 118 tumors and matched blood DNA from Chinese patients with UC using next-generation sequencing techniques, including 45 UTUC and 73 UCB. Two hundred twenty-six patients with UTUC and 350 patients with UCB for The Cancer Genome Atlas were acquired from the cbioportal.RESULTS:There were marked disparities in the mutational landscape for UC according to race and site of origin. Signature 22 for exposure to aristolochic acid was only observed in the UTUC cohort. Conversely, signature 6 for defective DNA mismatch repair only existed in the UCB cohort. Compared with UCB, UTUC had higher clonal and subclonal mutation numbers. TP53, PIK3CA, and FGFR3 mutations may be the driver genes for UTUC, whereas for UCB, the driver gene may be BRCA1. Patients with UTUC had lower PD-L1 than those with UCB. There was no significant difference in the number of DDR mutations, copy number variation counts, and tumor mutational burden between UTUC and UCB.CONCLUSION:UTUC and UCB exhibit significant differences in the prevalence of genomic landscape and carcinogenesis. Consequently, molecular subtypes differ according to location, and these results may imply the site-specific management of patients with urothelial carcinoma. Mutational signature may be used as a screening tool to assist clinical differential diagnosis between UTUC and UCB.IMPLICATIONS FOR PRACTICE:This study's findings lay the foundation for a deeper understanding of distinct molecular mechanisms and similar treatment opportunities between upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB) and had important implications for the site-specific management of patients with urothelial carcinoma. A comprehensive understanding of the biology of UTUC and UCB is needed to identify new drug targets in order to improve clinical outcomes.
Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of the clinicopathological features and survival outcomes

Liangyou Gu,Qing Ai,Qiang Cheng,Xin Ma,Baojun Wang,Qingbo Huang,Xintao Li,Peng Zhang,Kan Liu,Xupeng Zhao,Hongzhao Li,Xu Zhang

DOI: https://doi.org/10.1186/s12935-020-01626-9

IF: 6.429

2020-11-14

Cancer Cell International

Abstract:Abstract Background A systematic review and meta-analysis was performed to compare the clinicopathological features and survival outcomes between sarcomatoid variant (SV)-urothelial carcinoma of the bladder (UCB) and conventional UCB (C-UCB). Methods A comprehensive search of PubMed, Embase, and Cochrane Library was performed. Endpoints included clinicopathological features and survival outcomes (overall survival [OS], cancer-specific survival [CSS], and progression-free survival [PFS]). The survival benefits of neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy (AC) for SV-UCB also have been studied. Results A total of 8 observational studies were included. Patients with SV-UCB had a higher rate of ≥ stage pT3 (odds ratio [OR], 2.06; 95% confidence interval [CI], 1.64–2.59; p < 0.001) and a lower rate of concomitant carcinoma in situ (OR, 0.25; 95% CI, 0.09–0.72; p = 0.010). The other clinicopathological variables were similar between SV-UCB and C-UCB. With unadjusted data, patients with SV-UCB had a significant inferior OS (HR, 1.24; 95% CI, 1.07–1.44; p = 0.004) and CSS (HR, 2.08; 95% CI, 1.63–2.66; p < 0.001). However, after adjusted, SV-UCB had worse OS (HR, 1.41; 95% CI, 0.95–2.08; p = 0.090) and CSS (HR, 1.54; 95% CI, 0.95–2.52; p = 0.080) approaching the borderline of significance. For SV-UCB, NAC (HR, 0.73; 95% CI, 0.51–1.05; p = 0.090) and AC (HR, 0.88; 95% CI, 0.66–1.17; p = 0.370) seemed to have no benefit on OS. Conclusions Compared to C-UCB, SV-UCB was associated with more advanced disease and more inferior OS and CSS. NAC and AC had no survival benefit for SV-UCB.

oncology
Impact of upper tract urothelial carcinoma history on patients with non-muscle-invasive bladder cancer undergoing intravesical chemotherapy

Fei Wang,Jiaxiang Ji,Chin‐Hui Lai,Mingrui Wang,Haopu Hu,Yuxuan Song,Yiqing Du,Kexin Xu,Hao Hu,Tao Xu

DOI: https://doi.org/10.21203/rs.3.rs-3462324/v1

2023-01-01

Abstract:Abstract Purpose : This study was designed to evaluate the impact of upper tract urothelial carcinoma (UTUC) history on prognosis in patients with non-muscle-invasive bladder cancer (NMIBC) receiving intravesical chemotherapy. Patients and methods: We conducted a single center, retrospective study of 444 NMIBC patients who received intravesical chemotherapy after transurethral resection of the bladder cancer at Peking University People's Hospital from 2000 to 2015. Patients were divided into UTUC-NMIBC group (with UTUC history) and primary NMIBC group (without UTUC history). Demographic, clinical and pathologic factors were analyzed. Kaplan–Meier curves and the log-rank test were used to depict and compare recurrence-free survival (RFS) and progression-free survival (PFS) between the two groups. Multivariable Cox regression models were constructed to determine the variables associated with RFS and PFS. Results : Compared to the primary NMIBC group (n=410), the UTUC-NMIBC group (n=34) had an older median age (median age, 72.0 [65.0-81.0] vs 66.0 [58.0-75.0] years; P=0.007), a higher incidence of multiple tumors (52.9% vs 33.9%; P=0.026) and a higher recurrence rate (52.9% vs 30.7%; P=0.008) and worse RFS (P<0.001). In multivariate analysis, UTUC history was an independent risk factor for recurrence (hazard ratio=2.257; P=0.001), but not for progression. Interestingly, subgroup analysis indicated recent UTUC history (≤24 months between UTUC and NMIBC diagnoses) were associated with increased recurrence rates (73.7% vs 26.7%; P=0.014). Conclusion : Presence of UTUC history was an independent risk factor for recurrence in patients with NMIBC who received intravesical chemotherapy, which should be considered when developing treatment plan.
Altered gene expression during cellular aging.

J. R. Smith,O. Pereira-smith

DOI: https://doi.org/10.1139/G89-058

Genome

Abstract:The limited division potential of normal human diploid fibroblasts in culture represents a model system for cellular aging. Observations indicate cellular senescence is an active process. Senescent cells, although unable to divide, are actively metabolizing. Hybrids from fusion of normal and immortal human cells exhibit limited division potential, suggesting that the phenotype of cellular senescence is dominant and supporting the hypothesis that senescence is genetically programmed. Fusion of immortal human cell lines with each other has identified four complementation groups for indefinite division. This indicates that a limited number of specific genes or processes are involved in senescence. Senescent cells express highly abundant DNA synthesis inhibitory messenger RNAs and produce a surface membrane associated protein inhibitor of DNA synthesis not expressed in young cells. Senescent cell membranes were used as immunogen to generate three monoclonal antibodies reacting specifically with senescent but not young cells in several normal human cell lines. We have also found that fibronectin messenger RNA accumulates to high levels in senescent cells. The role of these changes in gene expression in senescence is being explored.
[Clinicopathologic Characteristics and Prognosis of Upper Tract Urothelial Carcinoma: an Analysis of 368 Radical Nephroureterectomy Specimens].

Y Wang,H Y He

DOI: https://doi.org/10.3760/cma.j.issn.0529-5807.2016.10.003

2016-01-01

Abstract:Objective: To evaluate the epidemiology, clinicopathological features and prognosis in upper tract urothelial carcinoma (UTUC) patients. Methods: All archival 368 UTUC cases that underwent radical nephroureterectomy between September 1999 and October 2014 were reviewed, and their clinicopathological features were analyzed. Follow-up time was 1-216 months, with a mean follow-up of 41 month. Results: One hundred and twenty-eight male and 240 female patients were included, with a mean age of 68 years ranging from 31 to 88 years. Tumor locations were classified in detail as follows: 148 renal pelvic tumors, 155 ureteral tumors, 58 renal pelvic and ureteral tumors, and 7 transitional tumors. Patients with history of renal transplantation (14.7%, 54/368) were more likely to develop UTUC before the age of 65 (P<0.01), with bilateral tract involved (P<0.01) and multifocal distributed (P=0.004). Histological grade was significantly associated with T stage (P<0.01), lympho-vascular involvement (P=0.001), neural invasion (P=0.005), carcinoma in situ (P=0.001) and extensive necrosis (P=0.020), while high-grade UTUC predominantly occurred in female patients (P=0.010) and histological variants (P<0.01). T stage was positively correlated with tumor size (P<0.01), lympho-vascular involvement (P<0.01), neural invasion (P<0.01) and lymph node metastasis (P=0.001). Furthermore, among the 214 followed-up cases, 76 died of the disease. Histological grade (P=0.002, P=0.005), T stage (P<0.01, P<0.01), lympho-vascular involvement (P=0.001, P=0.008), neural invasion (P<0.01, P=0.001) and extensive necrosis (P=0.017, P=0.023) were significantly associated with shorter overall survival and cancer specific survival of UTUC patients, respectively. In multivariable analyses, T stage (P<0.01, P<0.01) and extensive necrosis (P=0.004, P=0.014) were independent predictive factors of both overall survival and cancer specific survival, while neural invasion (P=0.007) and lymph node metastasis (P=0.007) were independent predictors of the overall survival. Conclusions: Chinese UTUC reveals its unique epidemiology. UTUC more commonly occurs in women and has a similar incidence between the renal pelvic and ureteral carcinoma. Patients with history of renal transplantation are prone to detect UTUC through physical examination rather than hematuria. Histological grade, T stage, lympho-vascular involvement, neural invasion and extensive necrosis are predictors of survival in UTUC patients, while advanced-stage and extensive necrosis are independent predictors of poor outcome.
Assessing the effect of subsequent bladder cancer following radical surgery for upper tract urothelial carcinoma: A systematic review and meta-analysis of prognostic studies

Haopu Hu,Shicong Lai,Mingrui Wang,Xiaodong Tang,Chin‐Hui Lai,Kexin Xu,Tao Xu,Hao Hu

DOI: https://doi.org/10.21203/rs.3.rs-3076189/v1

2023-01-01

Abstract:Abstract Background To investigate the effect of subsequent bladder cancer (SBCa) following radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). Methods PubMed, EMBASE, and the Cochrane Library were exhaustively searched for studies comparing oncological outcomes between SBCa and non-SBCa patients. Standard cumulative analyses using hazard ratios (HR) with 95% confidence intervals (CI) were performed using Review Manager (version 5.3). Results Five studies involving 2,057 patients were selected according to predefined eligibility criteria. Meta-analysis of cancer-specific survival (CSS) and overall survival (OS) revealed no significant differences between the SBCa group and non-SBCa group. However, subgroup analysis of pT0-3N0M0 patients suggested that people with SBCa have worse CSS (HR = 5.13, 95%CI 2.39–10.98, p < 0.0001)and OS (HR = 4.00, 95%CI 2.19–7.31, p < 0.00001). Conclusions SBCa appears to be associated with worse survival in people with early stage UTUC, overall. However, caution must be taken before recommendations are given because this interpretation is based upon very few clinical studies and a small sample. Research sharing more detailed surgical site descriptions, as well as enhanced outcome data collection and improved reporting is required to investigate the nuances further.
Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value

Dong Fang,Lei Zhang,Xuesong Li,Wei Yu,Nirmish Singla,Guangzhi Zhao,Gengyan Xiong,Yi Song,Qun He,Zhisong He,Liqun Zhou

DOI: https://doi.org/10.1245/s10434-014-4302-5

IF: 4.339

2015-01-01

Annals of Surgical Oncology

Abstract:Purpose To explore the characteristics, predictive risk factors, and prognostic effect of concomitant non-muscle-invasive bladder cancer (NMIBC) in patients with upper tract urothelial carcinoma (UTUC). Methods We evaluated 727 consecutive UTUC patients treated with radical resection between 2000 and 2012 in a high-volume center of China. Preoperative cystoscopy was performed in all patients. Patients with previous or concomitant total cystectomy were excluded. Results Overall, 73 patients (10.0 %) had NMIBC. Concomitant NMIBC was associated with previous bladder cancer ( p = 0.003), tumor located in ureter ( p = 0.008), multifocality ( p < 0.001), and preoperative renal insufficiency ( p = 0.023). The presence of concomitant NMIBC was predictive for lower tumor stage ( p = 0.019), papillary architecture ( p = 0.023), and organ-confined disease ( p T < 3 and N−, p = 0.006). The median follow-up duration was 57 months. The presence of concomitant NMIBC was a risk factor for bladder recurrence ( p < 0.001), and particularly in patients with non-muscle-invasive UTUCs, it affects cancer-specific survival (odds ratio 1.614, p = 0.030) and contralateral recurrence (odds ratio, 1.907, p = 0.016). Most concomitant NMIBC were found at the lateral wall or bladder neck, while most intravesical recurrences occurred near the site of surgery or posterior wall. Conclusions The most common site for concomitant NMIBC was lateral wall and bladder neck, and previous bladder cancer, tumor located in ureter, tumor multifocality, and preoperative renal insufficiency were risk factors for concomitant NMIBC. The presence of concomitant NMIBC is predictive for relative better pathologic outcomes but higher rate of bladder recurrence, while the effect on postoperative survival was limited with patients early-stage UTUCs. The potential mechanisms need further investigation.

[Steroid hormones in plasma and aqueous of bovine eye].

Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation

Upper urinary tract tumors developing after bladder transitional cell cancer

AB063. Comparisons of prognosis between urothelial carcinoma of the upper urinary tract and bladder with pT3-4 diseases

Incidence, characteristics, treatment strategies, and oncologic outcomes of synchronous bilateral upper tract urothelial carcinoma in the Chinese population.

Comparisons Of Prognosis Between Urothelial Carcinoma Of The Upper Urinary Tract And Bladder With Pt3-4 Cancer

MEMBRANE MARKERS OF LYMPHOCYTES IN LYMPHOMAS, MELANOMA AND LUPUS ERYTHEMATOSUS

Incidence, Characteristics, Treatment Strategies, and Oncologic Outcomes of Synchronous Bilateral Upper Tract Urothelial Carcinoma in the Chinese Population1these Authors Contribute Equally.

Predictive Value of Clinicopathological Markers for the Metachronous Bladder Cancer and Prognosis of Upper Tract Urothelial Carcinoma

Intravesical Recurrence after Radical Nephroureterectomy of Upper Urinary Tract Urothelial Carcinoma: A Large Population-Based Investigation of Clinicopathologic Characteristics and Survival Outcomes.

Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients

Genetic Alterations in Chromatin Regulatory Genes in Upper Tract Urothelial Carcinoma and Urothelial Bladder Cancer

Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy

Risk factors and survival outcomes of metachronous contralateral upper tract urothelial carcinoma

Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder

Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of the clinicopathological features and survival outcomes

Impact of upper tract urothelial carcinoma history on patients with non-muscle-invasive bladder cancer undergoing intravesical chemotherapy

Altered gene expression during cellular aging.

[Clinicopathologic Characteristics and Prognosis of Upper Tract Urothelial Carcinoma: an Analysis of 368 Radical Nephroureterectomy Specimens].

Assessing the effect of subsequent bladder cancer following radical surgery for upper tract urothelial carcinoma: A systematic review and meta-analysis of prognostic studies

Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value